Market Access News | pharmaphorum

News

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.

News

NICE backs five AI tools for bowel cancer screening

Five AI technologies used during a colonoscopy exam to help detect the early signs of bowel cancer have been backed for use by the NHS in England.

News

Bayer takes on Boehringer with FDA nod for lung cancer drug

Bayer joins Boehringer with FDA approval for a second-line, oral therapy for HER2-positive lung cancer, setting up a marketing battle in the US.

News

Bayer gets EU approval for menopause drug Lynkuet

Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

Alnylam's ATTR cardiomyopathy drug backed for NHS use

NICE backs five AI tools for bowel cancer screening

Bayer takes on Boehringer with FDA nod for lung cancer drug

Bayer gets EU approval for menopause drug Lynkuet

Approvals extend use of Roche, AbbVie drugs in lymphoma

US vulnerable to China's API dominance, says report

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks